LENZ Therapeutics (NASDAQ:LENZ) Announces Quarterly Earnings Results

LENZ Therapeutics (NASDAQ:LENZ) released its quarterly earnings data on Thursday. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10), FiscalAI reports. The business had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $4.20 million. LENZ Therapeutics had a negative net margin of 1,134.97% and a negative return on equity of 56.10%.

Here are the key takeaways from LENZ Therapeutics’ conference call:

• VIZZ product revenue and prescriptions each grew more than 50% sequentially in Q3, reaching $2.6 million in product revenue and more than 38,000 paid prescriptions. Telehealth contributed over half of incremental prescriptions, while gross-to-net remained strong at approximately 93%.
• LENZ is shifting to a consumer-led commercial model, supported by national television, digital advertising, telehealth, and pharmacy access. Management said VIZZ awareness exceeds 90% among eye-care professionals, with more than 15,000 prescribing ECPs and 94% U.S. market share based on Symphony data.
• The reorganization is expected to reduce the workforce to approximately 40 employees and cut annual operating expenses by more than 50%, with targeted 2027 operating expenses of $70 million-$75 million. More than 70% of projected spending will be directed toward consumer-focused sales and marketing.
• CEO Afschin Skjalm Paddock will step down effective December 1, 2026, with CFO Dan Chevallard becoming interim CEO while the board conducts a permanent search. LENZ expects approximately $5 million in one-time restructuring charges in Q4, and reported a Q3 net loss of $31 million, or $0.99 per share.
• LENZ ended Q3 with approximately $197.3 million in cash, cash equivalents, and marketable securities, and reported 11 ex-U.S. regulatory submissions under review. Management did not provide cash runway or revenue guidance.

LENZ Therapeutics Price Performance

LENZ stock traded down $0.44 during trading on Friday, hitting $3.05. The stock had a trading volume of 2,264,090 shares, compared to its average volume of 980,834. LENZ Therapeutics has a twelve month low of $2.99 and a twelve month high of $32.13. The company’s 50-day moving average price is $4.07 and its two-hundred day moving average price is $8.10. The stock has a market capitalization of $95.83 million, a P/E ratio of -0.68 and a beta of 0.64.

Analysts Set New Price Targets

A number of brokerages have recently commented on LENZ. Citigroup reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. Piper Sandler decreased their target price on shares of LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Monday, October 19th. Weiss Ratings downgraded shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 9th. Zacks Research upgraded shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, HC Wainwright dropped their price target on shares of LENZ Therapeutics to $16.00 and set a “buy” rating on the stock in a research report on Friday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, LENZ Therapeutics has an average rating of “Hold” and an average price target of $17.50.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.